Exhaled nitric oxide as a biomarker in COPD and related comorbidities

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Malerba, Mario ^a   Radaeli, Alessandro ^a   Olivini, Alessia ^a   Damiani, Giovanni ^b   Ragnoli, Beatrice ^a   Montuschi, Paolo ^c   Ricciardolo, Fabio L M ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b BRESCIA CIVIL HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE SEVERITY; EARLY DIAGNOSIS; EXPIRED AIR; HEART LEFT VENTRICLE FILLING PRESSURE; HUMAN; INTERSTITIAL LUNG DISEASE; ISCHEMIC HEART DISEASE; LUNG CIRCULATION; NITRATIVE STRESS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PSORIASIS VULGARIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; SYSTEMIC SCLEROSIS; VASOCONSTRICTION; BREATH ANALYSIS; EXHALATION; GENETICS; METABOLISM; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOLOGICAL MARKERS; BREATH TESTS; COMORBIDITY; EXHALATION; HUMANS; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84897886817     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/271918     Document Type: Review

References (79)

1. Barnes P. J., Celli B. R., Systemic manifestations and comorbidities of COPD. European Respiratory Journal 2009 33 5 1165 1185 2-s2.0-66749141807 10.1183/09031936.00128008
2. Fabbri L. M., Rabe K. F., From COPD to chronic systemic inflammatory syndrome? The Lancet 2007 370 9589 797 799 2-s2.0-34548277025 10.1016/S0140-6736(07)61383-X (Pubitemid 47320803)
3. Corsonello A., Antonelli Incalzi R., Pistelli R., Pedone C., Bustacchini S., Lattanzio F., Comorbidities of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 2011 17 1 S21 S28 2-s2.0-84855367507 10.1097/01.mcp.0000410744.75216.d0
4. Nussbaumer-Ochsner Y., Rabe K. F., Systemic manifestations of COPD. Chest 2011 139 1 165 173 2-s2.0-78651431729 10.1378/chest.10-1252
5. de Martinis M., Franceschi C., Monti D., Ginaldi L., Inflammation markers predicting frailty and mortality in the elderly. Experimental and Molecular Pathology 2006 80 3 219 227 2-s2.0-33646518593 10.1016/j.yexmp.2005.11.004
6. Sevenoaks M. J., Stockley R. A., Chronic obstructive pulmonary disease, inflammation and co-morbidity-a common inflammatory phenotype? Respiratory Research 2006 7, article 70 2-s2.0-33745209743 10.1186/1465-9921-7-70 (Pubitemid 43905819)
7. Ricciardolo F. L. M., di Stefano A., Sabatini F., Folkerts G., Reactive nitrogen species in the respiratory tract. European Journal of Pharmacology 2006 533 1-3 240 252 2-s2.0-33644778632 10.1016/j.ejphar.2005.12.057 (Pubitemid 43340016)
8. Ricciardolo F. L. M., Sterk P. J., Gaston B., Folkerts G., Nitric oxide in health and disease of the respiratory system. Physiological Reviews 2004 84 3 731 765 2-s2.0-2342482002 10.1152/physrev.00034.2003 (Pubitemid 38823765)
9. Ricciardolo F. L. M., cNOS-iNOS paradigm and arginase in asthma. Trends in Pharmacological Sciences 2003 24 11 560 563 2-s2.0-0242289523 10.1016/j.tips.2003.09.007 (Pubitemid 37357138)
10. Gelb A. F., Barnes P. J., George S. C., Ricciardolo F. L., Di Maria G., Zamel N., Review of exhaled oxide in chronic obstructive pulmonary disease. Journal of Breath Research 2012 6 4 047101
11. Saleh D., Ernst P., Lim S., Barnes P. J., Giaid A., Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. The FASEB Journal 1998 12 11 929 937 2-s2.0-0031857283 (Pubitemid 28359574)
12. Brindicci C., Kharitonov S. A., Ito M., Elliott M. W., Hogg J. C., Barnes P. J., Ito K., Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2010 181 1 21 30 2-s2.0-73849130301 10.1164/rccm.200904-0493OC
13. Ricciardolo F. L. M., Caramori G., Ito K., Capelli A., Brun P., Abatangelo G., Papi A., Chung K. F., Adcock I., Barnes P. J., Donner C. F., Rossi A., Di Stefano A., Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology 2005 116 5 1028 1035 2-s2.0-27644463766 10.1016/j.jaci.2005.06.034 (Pubitemid 41571783)
14. Brindicci C., Ito K., Resta O., Pride N. B., Barnes P. J., Kharitonov S. A., Exhaled nitric oxide from lung periphery is increased in COPD. European Respiratory Journal 2005 26 1 52 59 2-s2.0-21744442945 10.1183/09031936.04. 00125304 (Pubitemid 40945931)
15. Brindicci C., Ito K., Barnes P. J., Kharitonov S. A., Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers. Chest 2007 132 2 581 588 2-s2.0-34548012407 10.1378/chest.06-3046 (Pubitemid 47282392)
16. Hansel T. T., Kharitonov S. A., Donnelly L. E., Erin E. M., Currie M. G., Moore W. M., Manning P. T., Recker D. P., Barnes P. J., A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. The FASEB Journal 2003 17 10 1298 1300 2-s2.0-0038604348
17. Singh D., Richards D., Knowles R. G., Schwartz S., Woodcock A., Langley S., O'Connor B. J., Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. American Journal of Respiratory and Critical Care Medicine 2007 176 10 988 993 2-s2.0-36249008584 10.1164/rccm.200704-588OC (Pubitemid 350127842)
18. Osoata G. O., Hanazawa T., Brindicci C., Ito M., Barnes P. J., Kharitonov S., Ito K., Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009 135 6 1513 1520 2-s2.0-66649127216 10.1378/chest.08-2105
19. Pijnenburg M. W., Hofhuis W., Hop W. C., de Jongste J. C., Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005 60 3 215 218 2-s2.0-14944353086 10.1136/thx.2004.023374 (Pubitemid 40380280)
20. Zacharasiewicz A., Wilson N., Lex C., Erin E. M., Li A. M., Hansel T., Khan M., Bush A., Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. American Journal of Respiratory and Critical Care Medicine 2005 171 10 1077 1082 2-s2.0-18644373492 10.1164/rccm.200409-1242OC (Pubitemid 40663717)
21. Smith A. D., Cowan J. O., Brassett K. P., Filsell S., McLachlan C., Monti-Sheehan G., Herbison C. P., Taylor D. R., Exhaled nitric oxide: a predictor of steroid response. American Journal of Respiratory and Critical Care Medicine 2005 172 4 453 459 2-s2.0-23644431748 10.1164/rccm.200411-1498OC (Pubitemid 41117391)
22. Dweik R. A., Boggs P. B., Erzurum S. C., Irvin C. G., Leigh M. W., Lundberg J. O., Olin A.-C., Plummer A. L., Taylor D. R., An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American Journal of Respiratory and Critical Care Medicine 2011 184 5 602 615 2-s2.0-80052438246 10.1164/rccm.9120-11ST
23. Sterk P. J., de Gouw H. W. F. M., Ricciardolo F. L. M., Rabe K. F., Exhaled nitric oxide in COPD: glancing through a smoke screen. Thorax 1999 54 7 565 567 2-s2.0-0033062529 (Pubitemid 29296672)
24. Kharitonov S. A., Robbins R. A., Yates D., Keatings V., Barnes P. J., Acute and chronic effects of cigarette smoking on exhaled nitric oxide. American Journal of Respiratory and Critical Care Medicine 1995 152 3 892 896 2-s2.0-0029145012
25. Clini E., Cremona G., Campana M., Scotti C., Pagani M., Bianchi L., Giordano A., Ambrosino N., Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale: correlates with echo-doppler assessment. American Journal of Respiratory and Critical Care Medicine 2000 162 2, part I 446 450 2-s2.0-0033841145 (Pubitemid 30647181)
26. Agustí A. G. N., Villaverde J. M., Togores B., Bosh M., Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal 1999 14 3 523 528 2-s2.0-0032884546 10.1034/j.1399-3003.1999.14c08.x (Pubitemid 29479714)
27. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., Ciaccia A., Fabbri L. M., Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000 162 5 1773 1777 2-s2.0-0033711405
28. Kunisaki K. M., Rice K. L., Janoff E. N., Rector T. S., Janoff E. N., Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Therapeutic Advances in Respiratory Disease 2008 2 2 55 64 2-s2.0-66149150949 10.1177/1753465808088902 (Pubitemid 351472131)
29. Dummer J. F., Epton M. J., Cowan J. O., Cook J. M., Condliffe R., Landhuis C. E., Smith A. D., Taylor D. R., Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. American Journal of Respiratory and Critical Care Medicine 2009 180 9 846 852 2-s2.0-70350450276 10.1164/rccm.200905-0685OC
30. de Laurentiis G., Maniscalco M., Cianciulli F., Stanziola A., Marsico S., Lundberg J. O., Weitzberg E., Sofia M., Exhaled nitric oxide monitoring in COPD using a portable analyzer. Pulmonary Pharmacology and Therapeutics 2008 21 4 689 693 2-s2.0-47049121161 10.1016/j.pupt.2008.04.006
31. Antus B., Barta I., Horvath I., Csiszer E., Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010 15 3 472 477 2-s2.0-77950203510 10.1111/j.1440-1843.2010.01711. x
32. Maziak W., Loukides S., Culpitt S., Sullivan P., Kharitonov S. A., Barnes P. J., Exhaled nitric oxide in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1998 157 3 998 1002 2-s2.0-0031898729
33. Soter S., Barta I., Antus B., Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation 2013 36 5 1178 1185 10.1007/s10753-013-9653-8
34. Aboussuan L. S., Stoller J. K., New developments in alpha 1-antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine 1999 20 301 310 (Pubitemid 29379735)
35. Machado R. F., Stoller J. K., Laskowski D., Zheng S., Lupica J. A., Dweik R. A., Erzurum S. C., Low levels of nitric oxide and carbon monoxide in α 1-antitrypsin deficiency. Journal of Applied Physiology 2002 93 6 2038 2043 2-s2.0-0036892697 (Pubitemid 35379329)
36. Malerba M., Clini E., Cremona G., Radaeli A., Bianchi L., Corda L., Pini L., RICClARDOLO F., Grassi V., Ambrosino N., Exhaled nitric oxide in patients with PiZZ phenotype-related α 1-anti-trypsin deficiency. Respiratory Medicine 2001 95 6 520 525 2-s2.0-0034937770 10.1053/rmed.2001.1082 (Pubitemid 32622007)
37. Malerba M., Ragnoli B., Radaeli A., Exhaled nitric oxide levels in alpha-1-antitrypsin PiMZ subjects. Journal of Internal Medicine 2009 265 3 382 387 2-s2.0-60349114163 10.1111/j.1365-2796.2008.02021.x
38. Malerba M., Radaeli A., Ceriani L., Tantucci C., Grassi V., Airway hyperresponsiveness in a large group of subjects with α 1-antitrypsin deficiency: a cross-sectional controlled study. Journal of Internal Medicine 2003 253 3 351 358 2-s2.0-0037335767 10.1046/j.1365-2796.2003.01083.x (Pubitemid 36315207)
39. Heresi G. A., Dweik R. A., Pulmonary hypertension: evaluation and management. Comprehensive Therapy 2007 33 3 150 161 2-s2.0-36949037310 10.1007/s12019-007-0014-0 (Pubitemid 350242496)
40. Ghamra Z. W., Dweik R. A., Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleveland Clinic Journal of Medicine 2003 70 supplement 1 S2 S8 2-s2.0-2342667629
41. Archer S., Rich S., Primary pulmonary hypertension: a vascular biology and translational research 'work in progress'. Circulation 2000 102 22 2781 2791 2-s2.0-0034727717
42. Dweik R. A., Pulmonary hypertension and the search for the selective pulmonary vasodilator. The Lancet 2002 360 9337 886 887 2-s2.0-0037152102 10.1016/S0140-6736(02)11067-1 (Pubitemid 35283827)
43. Dweik R. A., Laskowski D., Abu-Soud H. M., Kaneko F. T., Hutte R., Stuehr D. J., Erzurum S. C., Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. Journal of Clinical Investigation 1998 101 3 660 666 2-s2.0-0032005770 (Pubitemid 28084250)
44. Kaneko F. T., Arroliga A. C., Dweik R. A., Comhair S. A., Laskowski D., Oppedisano R., Thomassen M. J., Erzurum S. C., Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 1998 158 3 917 923 2-s2.0-0031783406 (Pubitemid 28449461)
45. Malerba M., Radaeli A., Ragnoli B., Airo' P., Corradi M., Ponticiello A., Zambruni A., Grassi V., Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest 2007 132 2 575 580 2-s2.0-34548022633 10.1378/chest.06-2929 (Pubitemid 47282391)
46. Dweik R. A., The lung in the balance: arginine, methylated arginines, and nitric oxide. American Journal of Physiology 2007 292 1 L15 L17 2-s2.0-33846188567 10.1152/ajplung.00322.2006 (Pubitemid 46103425)
47. Özkan M., Dweik R. A., Laskowski D., Arroliga A. C., Erzurum S. C., High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001 179 4 233 243 2-s2.0-0035722661 10.1007/s004080000064 (Pubitemid 34194207)
48. Girgis R. E., Frost A. E., Hill N. S., Horn E. M., Langleben D., McLaughlin V. V., Oudiz R. J., Robbins I. M., Seibold J. R., Shapiro S., Tapson V. F., Barst R. J., Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Annals of the Rheumatic Diseases 2007 66 11 1467 1472 2-s2.0-34948865560 10.1136/ard.2007.069609 (Pubitemid 350032654)
49. Machado R. F., Londhe Nerkar M.-V., Dweik R. A., Hammel J., Janocha A., Pyle J., Laskowski D., Jennings C., Arroliga A. C., Erzurum S. C., Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radical Biology and Medicine 2004 37 7 1010 1017 2-s2.0-4444354032 10.1016/j.freeradbiomed. 2004.06.039 (Pubitemid 39164583)
50. Black C. M., du Bois R. M., Clements P., Furst D. E., Pulmonary organ involvement. Systemic Sclerosis 1996 Baltimore, Md, USA Williams and Wilkins 299 333
51. Ungerer R. G., Tashkin D. P., Furst D., Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. American Journal of Medicine 1983 75 1 65 74 2-s2.0-0020520743 (Pubitemid 13060288)
52. Prescott R. J., Freemont A. J., Jones C. J. P., Hoyland J., Fielding P., Sequential dermal microvascular and perivascular changes in the development of scleroderma. Journal of Pathology 1992 166 3 255 263 2-s2.0-0026604019
53. Harrison N. K., Myers A. R., Corrin B., Soosay G., Dewar A., Black C. M., Du Bois R. M., Turner-Warwick M., Structural features of interstitial lung disease in systemic sclerosis. American Review of Respiratory Disease 1991 144 3, part I 706 713 2-s2.0-0025951772
54. Stamler J. S., Loh E., Roddy M.-A., Currie K. E., Creager M. A., Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994 89 5 2035 2040 2-s2.0-0028314525 (Pubitemid 24142778)
55. Al-Ali M. K., Howarth P. H., Nitric oxide and the respiratory system in health and disease. Respiratory Medicine 1998 92 5 701 715 2-s2.0-0031865874 10.1016/S0954-6111(98)90000-2 (Pubitemid 28279442)
56. Barnes P. J., Belvisi M. G., Nitric oxide and lung disease. Thorax 1993 48 10 1034 1043 2-s2.0-0027427343 (Pubitemid 23319631)
57. Eiserich J. P., Patel R. P., O'Donnell V. B., Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. Molecular Aspects of Medicine 1998 19 4-5 221 357 2-s2.0-0032464635 10.1016/S0098-2997(99)00002-3 (Pubitemid 29184931)
58. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism 1980 23 5 581 590 2-s2.0-0018887574
59. Macdonald P., Schyvens C., Winlaw D., The role of nitric oxide in heart failure: potential for pharmacological intervention. Drugs and Aging 1996 8 6 452 458 2-s2.0-0029956160
60. Wilson Tang W. H., Tong W., Shrestha K., Wang Z., Levison B. S., Delfraino B., Hu B., Troughton R. W., Klein A. L., Hazen S. L., Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. European Heart Journal 2008 29 20 2506 2513 2-s2.0-54149088882 10.1093/eurheartj/ehn360
61. Hare J. M., Nguyen G. C., Massaro A. F., Drazen J. M., Stevenson L. W., Colucci W. S., Fang J. C., Johnson W., Givertz M. M., Lucas C., Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure. Journal of the American College of Cardiology 2002 40 6 1114 1119 2-s2.0-0037130789 10.1016/S0735-1097(02)02117-4
62. Agostoni P., Bussotti M., Exhaled nitric oxide and exercise performance in heart failure. Archives of Physiology and Biochemistry 2003 111 4 293 296 2-s2.0-14344258002 10.1080/13813450312331337423 (Pubitemid 40292062)
63. Seshadri N., Dweik R. A., Laskowski D., Pothier C., Rodriguez L., Young J. B., Migrino R. Q., Dysregulation of endogenous carbon monoxide and nitric oxide production in patients with advanced ischemic or nonischemic cardiomyopathy. American Journal of Cardiology 2003 92 7 820 823 2-s2.0-0141682411 10.1016/S0002-9149(03)00890-7 (Pubitemid 37163577)
64. Katz S. D., Hryniewicz K., Hriljac I., Balidemaj K., Dimayuga C., Hudaihed A., Yasskiy A., Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005 111 3 310 314 2-s2.0-12844270491 10.1161/01.CIR.0000153349.77489.CF (Pubitemid 40165337)
65. Schuster A., Thakur A., Wang Z., Borowski A. G., Thomas J. D., Tang W. H., Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension. Journal of Cardiac Failure 2012 18 10 799 803
66. Simon D. I., Stamler J. S., Jaraki O., Keaney J. F., Osborne J. A., Francis S. A., Singel D. J., Loscalzo J., Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arteriosclerosis and Thrombosis 1993 13 6 791 799 2-s2.0-0027267083 (Pubitemid 23164681)
67. deCaterina R., LibbyP, Peng H.-B., Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and pro inflammatory cytokines. Journal of Clinical Investigation 1995 96 60 68
68. Ignarro L. J., Napoli C., Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Current Atherosclerosis Reports 2004 6 4 281 287 2-s2.0-5444239280 (Pubitemid 39359467)
69. Salonen I., Huttunen K., Hirvonen M.-R., Dufva J., Groundstroem K., Dufva H., Salonen R. O., Exhaled nitric oxide and atherosclerosis. European Journal of Clinical Investigation 2012 42 8 873 880 2-s2.0-84858255793 10.1111/j.1365-2362.2012.02662.x
70. Pathirana D., Ormerod A. D., Saiag P., Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of the European Academy of Dermatology and Venereology 2010 133 2 377 385 2-s2.0-71949098360 10.1111/j.1468-3083.2009.03504.x
71. Parisi R., Symmons D. P., Griffiths C. E., Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology 2013 133 2 377 385
72. Al-Mutairi N., Al-Farag S., Al-Mutairi A., Comorbidities associated with psoriasis: an experience from the Middle East. Journal of Dermatology 2010 37 2 146 155 2-s2.0-76249101957 10.1111/j.1346-8138.2009.00777.x
73. Dreiher J., Weitzman D., Shapiro J., Davidovici B., Cohen A. D., Psoriasis and chronic obstructive pulmonary disease: a case-control study. British Journal of Dermatology 2008 159 4 956 960 2-s2.0-51849111494 10.1111/j.1365-2133.2008.08749.x
74. Chiang Y.-Y., Lin H.-W., Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. Journal of the European Academy of Dermatology and Venereology 2012 26 1 59 65 2-s2.0-83755225180 10.1111/j.1468-3083.2011.04009.x
75. Mahajan R., Handa S., Pathophysiology of psoriasis. Indian Journal of Dermatology, Venereology and Leprology 2013 79 S1 S9
76. Cals-Grierson M.-M., Ormerod A. D., Nitric oxide function in the skin. Nitric Oxide 2004 10 4 179 193 2-s2.0-3242719521 10.1016/j.niox.2004.04.005 (Pubitemid 38953389)
77. Bruch-Gerharz D., Schnorr O., Suschek C., Beck K.-F., Pfeilschifter J., Ruzicka T., Kolb-Bachofen V., Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. American Journal of Pathology 2003 162 1 203 211 2-s2.0-0037223634 (Pubitemid 36042002)
78. Ormerod A. D., Weller R., Copeland P., Benjamin N., Ralston S. H., Grabowksi P., Herriot R., Detection of nitric oxide and nitric oxide synthases in psoriasis. Archives of Dermatological Research 1998 290 1-2 3 8 2-s2.0-0031882746 10.1007/s004030050268 (Pubitemid 28127761)
79. Gabr S. A., Al-Ghadir A. H., Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. Archives of Dermatological Research 2012 304 6 451 457 2-s2.0-84858029018 10.1007/s00403-012-1230-8